Skip to main content
glpverdict
Editorial medical reviewFDA & peer-reviewed sourcesUpdated weeklyMedically reviewed content
HomeCompareMounjaro vs Ozempic

Medication comparison

Mounjaro vs Ozempic

Mounjaro and Ozempic are both prescription medications (GIP/GLP-1 dual receptor agonist vs GLP-1 receptor agonist) used for Type 2 diabetes. The table below compares FDA-approved indications, dosing, weight-loss outcomes, side effects, contraindications, and current pricing — all sourced from the manufacturer prescribing information.

Find a provider for Mounjaro or Ozempic

Affiliate disclosure: we earn commission on signups. Editorial ranking stays independent.

This is general drug information, not medical advice. Talk to a licensed clinician before starting, stopping, or switching medication.

Overview

PropertyMounjaroOzempic
Generic nametirzepatidesemaglutide
Drug classGIP/GLP-1 dual receptor agonistGLP-1 receptor agonist
ManufacturerEli LillyNovo Nordisk
Brand namesMounjaroOzempic

Approved uses

PropertyMounjaroOzempic
Approved indicationsType 2 diabetesType 2 diabetes

Dosing

PropertyMounjaroOzempic
Typical dosingTitrate to 15 mg (weekly SC injection)Titrate to 2.0 mg (weekly SC injection)

Side effects & warnings

PropertyMounjaroOzempic
Top side effectsNausea (29.6%), Diarrhea (23%), Vomiting (12.6%)Nausea (20.3%), Vomiting (9.2%), Diarrhea (8.5%)
Contraindications
Boxed warningYesYes

Special populations

PropertyMounjaroOzempic
PregnancyC — Discontinue at least 1 month before a planned pregnancy.C — Discontinue at least 2 months before a planned pregnancy.

Storage

PropertyMounjaroOzempic
StorageRefrigerate before first use. After first use, room temperature up to 21 days.Refrigerate before first use. After first use, room temperature up to 56 days. Protect from light.

Cost

PropertyMounjaroOzempic
Avg monthly cost$1023.04$935.77

FDA boxed warning

Mounjaro: Risk of thyroid C-cell tumors. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).

Ozempic: Risk of thyroid C-cell tumors. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).

Already on Mounjaro and considering Ozempic?

Reverse switch — usually for insurance, side-effect tolerance, or shortage reasons.

Read the switching guide

Frequently asked

What is the difference between Mounjaro and Ozempic?

Mounjaro is tirzepatide (GIP/GLP-1 dual receptor agonist) and Ozempic is semaglutide (GLP-1 receptor agonist). They have different active ingredients and slightly different side-effect profiles.

Is Mounjaro or Ozempic more effective for weight loss?

Head-to-head trial data favors tirzepatide-based medications (Mounjaro, Zepbound) over semaglutide-based medications (Ozempic, Wegovy) in average percent weight loss. SURMOUNT-1 reported ~20.9% mean weight loss on tirzepatide 15 mg; STEP 1 reported ~14.9% on semaglutide 2.4 mg over comparable timelines.

Can I switch between Mounjaro and Ozempic?

Yes — see our directional switching guide at /switching/mounjaro-to-ozempic for FDA-label dose conversion and what to expect during the transition.

Other GLP-1 head-to-head comparisons

More medication context

Tools and guides that pair with this comparison.

Affiliate disclosure: we earn commissions when readers sign up through our links. Editorial ranking is independent.